Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”?

Previous articleYeast Genome 2.0 Fully Coded, One-Third Uploaded
Next articleAmerican Health Care Plan—Yay or Ney